Second-generation pharmacological chaperones:

HIGHLIGHTS

  • who: Beyond Inhibitors and collaborators from the (UNIVERSITY) have published the paper: Second-Generation Pharmacological Chaperones:, in the Journal: (JOURNAL)
  • future: Studies including for instance crystallographic data would be necessary to demonstrate the allosteric binding of N-butyl-l-deoxynojirimycin. Several promising Gcase non-inhibitory PCs have been uncovered and investigated for GD1 GD2 but also Parkinson disease and further pharmaco-kinetic and -dynamic studies are needed to 6 of 21 develop the most effective analogs as well as mechanistic studies to identify the allosteric binding_sites involved.

SUMMARY

    If most of . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?